Literature DB >> 8882087

Pulmonary hypertension: NO therapy?

S Adnot1, B Raffestin.   

Abstract

Endothelium-derived nitric oxide (NO) is a powerful pulmonary vasodilator which also prevents adhesion and aggregation of platelets, controls growth of smooth muscle, and influences the expression of growth promoting and vasoactive substances. Impaired endothelial NO production contributes to pulmonary vasoconstriction and vascular remodelling in several forms of pulmonary hypertension. Exogenous NO gas delivered via the airspaces is a selective pulmonary vasodilator now used as treatment in various lung disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882087      PMCID: PMC472503          DOI: 10.1136/thx.51.7.762

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

Review 1.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs.

Authors:  J R Fineman; J Wong; F C Morin; L M Wild; S J Soifer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

3.  Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats.

Authors:  C Kouyoumdjian; S Adnot; M Levame; S Eddahibi; H Bousbaa; B Raffestin
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

4.  Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension.

Authors:  H I Palevsky; W Long; J Crow; A P Fishman
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

5.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.

Authors:  R De Caterina; P Libby; H B Peng; V J Thannickal; T B Rajavashisth; M A Gimbrone; W S Shin; J K Liao
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.

Authors:  R M Tuder; B E Flook; N F Voelkel
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia.

Authors:  S Kourembanas; L P McQuillan; G K Leung; D V Faller
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension.

Authors:  S Adnot; C Kouyoumdjian; C Defouilloy; P Andrivet; S Sediame; R Herigault; M D Fratacci
Journal:  Am Rev Respir Dis       Date:  1993-08

9.  Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia.

Authors:  S Adnot; B Raffestin; S Eddahibi; P Braquet; P E Chabrier
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

10.  Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms.

Authors:  L P McQuillan; G K Leung; P A Marsden; S K Kostyk; S Kourembanas
Journal:  Am J Physiol       Date:  1994-11
View more
  1 in total

Review 1.  New ideas on the pathophysiology and treatment of lung disease.

Authors:  D F Rogers; G J Laurent
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.